Donepezil, a centrally acting acetylcholinesterase inhibitor, alleviates learning deficits in hypocholinergic models in rats

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 22, Issue 2, 2000, Pages 89-95

  Ogura, Hiroo ^a   Kosasa, T ^a   Kuriya, Y ^a   Yamanishi, Y ^b  

^a EISAI CO LTD   (Japan)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Acetylcholinesterase inhibitor; Donepezil; Learning; Medial septum; Nucleus basalis magnocellularis; Rats; Scopolamine; Tacrine

Indexed keywords

ACETYLCHOLINESTERASE; CHOLINESTERASE INHIBITOR; DONEPEZIL;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHEMICAL STRUCTURE; CHOLINERGIC SYSTEM; CONTROLLED STUDY; DRUG EFFECT; LEARNING DISORDER; MAGNOCELLULAR NUCLEUS; MALE; MAZE TEST; MOTOR PERFORMANCE; NONHUMAN; OLIVARY NUCLEUS; RAT;

EID: 0034103787     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: 10.1358/mf.2000.22.2.796070     Document Type: Article

References (44)

1. Evans, D.A., Funkenstein, H., Albert, M.S. et al. Prevalence of Alzheimer's disease in a community population of older persons. J Am Med Assoc 1989, 262: 2551-6.
2. Coyle, J.T., Price, D.L., DeLong, M.R. Alzheimer's disease: A disorder of cortical cholinergic innervation. Science 1983, 219: 1184-90.
3. Bowen, D.M., Smith, C.B., White, P., Davison, A.N. Neuro-transmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain, 1976, 99: 459-95.
4. Davies, P., Maloney, A.J.R. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976, ii: 1403.
5. Perry, E.K., Gibson, P.H., Blessed, G., Tomlinson, B.E. Neuro-transmitter enzyme abnormalities in senile dementia. J Neurol Sci 1977, 34: 247-65.
6. Whitehouse, P.J., Price, D.L., Struble, R.G., Clark, J.T., Coyle, J.T., DeLong, M.R. Alzheimer's disease and senile dementia: Loss of neurons in the basal forebrain. Science 1982, 215: 1237-9.
7. Perry, E.K., Tomlinson, B.E., Blessed, G., Bergmann, K., Gibson, P.H., Perry, R.H. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J 1978, 2: 1457-9.
8. Drachman, D.A., Leavitt, J. Human memory and the cholinergic system. Arch Neurol 1974, 30: 113-21.
9. Molchan, S.E., Martinez, R.A., Hill, J.L et al., Increased cognitive sensitivity to scopolamine with age and a perspective on the scopolamine model. Brain Res Rev 1992, 17: 215-26.
10. Davis, K.L., Mohs, R.C. Enhancement of memory processes in Alzheimer's disease with multiple-dose intravenous physostigmine. Am J Psychiatry 1982, 139: 1421-4.
11. Mohs, R.C., Davis, B.M., Johns, C.A. et al. Oral physostigmine treatment of patients with Alzheimer's disease. Am J Psychiatry 1985, 142: 28-33.
12. Farlow, M., Gracon, S.I., Hershey, L.A., Lewis, K.W., Sadowsky, C.H., Dolan-Ureno, J. A controlled trial of tacrine in Alzheimer's disease. J Am Med Assoc 1992, 268: 2523-9.
13. Gibson, M., Moore, T., Smith, C.M., Whelpton, R. Physostigmine concentrations after oral doses. Lancet 1985, 1: 695-6.
14. Sharpless, N.S., Thal, L.J. Plasma physostigmine concentrations after oral administration. Lancet 1985, 1: 1397-8.
15. Johns, C.A., Haroutunian, V., Greenwald, B.S. et al. Development of cholinergic drugs for the treatment of Alzheimer's disease. Drug Develop Res 1985, 5: 77-96.
16. Summers, W.K., Majovski, L.V., Marsh, G.M., Tachiki, K., Kling, A. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N Engl J Med 1986, 315: 1241-5.
17. Gauthier, S., Masson, H., Gauthier, L. et al. Tetrahydroaminoacridine and lecithin in Alzheimer's disease. In: Current Research in Alzheimer Therapy. Giacobini, E., Becker, R. (Eds.). Taylor and Francis: London 1988, 237-45.
18. Ames, D.J., Bhatal, P.S., Davies, B.M., Fraser, J.R.E. Hepatotoxicity of tetrahydroaminoacridine. Lancet 1988, i: 887.
19. Yamanishi, Y., Ogura, H., Kosasa, T., Araki, S., Sawa, Y., Yamatsu, K. Inhibitory action of E2020, a novel acetylcholinesterase inhibitor, on cholinesterase: Comparison with other inhibitors. In: Basic, Clinical, and Therapeutic Aspects of Alzheimer's and Parkinson's Diseases. Plenum Press 1991, 2: 409-13.
20. Sugimoto, H., Iimura, Y., Yamanishi, Y., Yamatsu, K. Synthesis and structure-activity relationships of acetylcholinesterase inhibitors: I-Benzyl-4-[(5,6-dimethoxy-I-oxoidanon-2-yl)methyl]piperidine hydrochloride and related compounds. J Med Chem 1995, 38: 4821-9.
21. Kosasa, T., Kuriya, Y., Matsui, K., Yamanishi, Y. Effect of donepezil hydrochloride (E2020) on basal concentration of extracellular acetylcholine in the hippocampus of rats. Eur J Pharmacol 1999, 380: 101-7.
22. Kosasa, T., Kuriya, Y., Yamanishi, Y. Effect of donepezil hydrochloride (E2020) on extracellular acetylcholine concentration in the cerebral cortex of rats. Jpn J Pharmacol 1999, 81: 216-22.
23. Rogers, S.L., Doody, R.S., Mohs, R., Friedhoff, L.T. The Donepezil Study Group. Donepezil improves cognitive and global function in Alzheimer's disease: A 15-week double-blind, placebo-controlled study. Arch Intern Med 1998, 158: 1021-31.
24. Rogers, S.L., Farlow, M.R., Doody, R.S., Mohs, R., Friedhoff, L.T. The Donepezil Study Group. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998, 50: 136-45.
25. Rogers, S.L., Friedhoff, L.T. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: An interim analysis of the results of a US multicenter open-label extension study. Eur Neuropsychopharmacol 1998, 8: 67-75.
26. Mihara, M., Ohnishi, A., Tomono, Y. et al. Pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy male volunteers. Int J Clin Pharmacol Therap 1993, 31: 223-9.
27. Paxinos, G., Watson, C. The Rat Brain in Stereotaxic Coordinates. Academic Press, 1982.
28. Hiraga, Y., Iwasaki, T. Effects of cholinergic and monoaminergic antagonists and tranquilizers upon spatial memory in rats. Pharmacol Biochem Behav 1984, 20: 205-7.
29. Lehmann, J., Nagy, J.L., Atmadja, S., Fibiger, H.C. The nucleus basalis magnocellularis: The origin of a cholinergic projection to the neocortex of the rat. Neuroscience 1980, 5: 1161-74.
30. Mesulam, M-M., Mufson, E.J., Wainer, B.H., Levey, A.I. Central cholinergic pathways in the rat: An overview based on an alternative nomenclature (Ch1-Ch6). Neuroscience 1983. 10: 1185-201.
31. Smith, G. Animal models of Alzheimer's disease: Experimental cholinergic denervation. Brain Res Rev 1988, 13: 103-18.
32. Olton, D.S., Wenk, G.L. Dementia: Animal models of the cognitive impairments following damage to the basal forebrain cholinergic system. Brain Res Bull 1990, 25: 499-502.
33. Dunnett, S.B., Whishaw, I.Q., Jones, G.H., Bunch, S.T. Behavioral, biochemical and histochemical effects of different neurotoxic amino acids injected into nucleus basalis magnocellularis of rats. Neuroscience 1987, 20: 653-69.
34. Kosasa, T., Kuriya, Y. Matsui, K., Yamanishi, Y. Inhibitory effect of orally administered donepezil hydrochloride (E2020), a novel treatment for Alzheimer's disease, on cholinesterase activity in rats. Eur J Pharmacol 1999, 386: 7-13.
35. Ball, M.J. Neuronal loss, neurofibrillary tangles and granulovacuolar degeneration in the hippocampus with aging and dementia. Acta Neuropathol (Berlin) 1977, 37: 111-8.
36. Gray, J.A., McNaughton, N. Comparison between the behavioral effects of septal and hippocampal lesions: A review. Neurosci Biobehav Reviews 1982, 7: 119-88.
37. Riekkinen, P. Jr., Riekkinen, M., Sirvio, J. Effects of tetrahydroaminoacridine on spatial navigation of nucleus-basalis-and frontal-cortex-lesioned rats. Pharmacol Biochem Behav 1992, 41: 637-41.
38. Olton, D.S., Samuelson, R.J. Remembrance of places passed: Spatial memory in rats. J Exp Psychol (Anim Behav) 1976, 2: 97-115.
39. Olton, D.S. The radial arm maze as a tool in behavioral pharmacology. Physiol Behav 1987, 40: 793-7.
40. Walsh, T.J., Chrobak, J.J. The use of the radial-arm maze in neurotoxicology. Physiol Behav 1987, 40: 799-803.
41. Eckerman, D.A., Gordon, W.A., Edwards, J.D., MacPhail, R.C., Gage, M.I. Effects of scopolamine, pentobarbital, and amphetamine on radial arm maze performance in the rat. Pharmacol Biochem Behav 1980, 12: 592-602.
42. Stevens, R. Scopolamine impairs spatial maze performance in rats. Physiol Behav 1981, 27: 385-6.
43. Higashida, A., Ogawa, N. Differences in the acquisition process and the effect of scopolamine on the radial maze performance in three strain of rats. Pharmacol Biochem Behav 1987, 27: 483-9.
44. Rogers, S.L., Friedhoff, L.T., The Donepezil Study Group. The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicenter, randomized, double-blind, placebo-controlled trial. Dementia 1996, 7: 293-303.